Lycia Therapeutics, Inc.

Biotechnology · SOUTH SAN FRANCISCO, CA

BiotechnologySEC Form D

Lycia Therapeutics, Inc. filed a Form D with the U.S. Securities and Exchange Commission on June 25, 2026, reporting $75,000,000 raised.

Incorporated in Delaware and based in SOUTH SAN FRANCISCO, CA, it operates in the Biotechnology sector.

Companies file a Form D within 15 days of the first sale of securities in a private offering under Regulation D — an early, public signal that Lycia Therapeutics, Inc. has raised capital from private investors.

Browse more recently funded companies in Biotechnology.

Executives & Directors

  • William RieflinDirector
  • Clare OzawaDirector
  • Ming FangDirector
  • Laurent FischerDirector
  • Tim AndersonDirector
  • Aetna Wun TrombleyExecutive Officer · Director
  • Amy BachrodtExecutive Officer

Recently funded in Biotechnology

Other companies that recently filed a Form D

$19.1MRaised

Rapalogix Health, Inc.

BiotechnologyCARLSBAD, CA
Jun 22, 2026View SEC Form D
$150.0KRaised

Chickadee Biomedicines, Inc.

BiotechnologyBOSTON, MA
Jun 22, 2026View SEC Form D
$500.0KRaised

Boston Interactome, Inc.

BiotechnologyALLSTON, MA
Jun 18, 2026View SEC Form D
$3.8MRaised

DINYA DNA, Inc.

BiotechnologyOAKLAND, CA
Jun 18, 2026View SEC Form D
$6.5MRaised

REGENTIS BIOMATERIALS LTD.

BiotechnologyHERZLIYA, L3
Jun 17, 2026View SEC Form D